Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Corbus Pharmaceuticals Advances Oncology Research with First Patient Dosed in CRB-601 Clinical Trial for Advanced Solid Tumors

Corbus Pharmaceuticals begins Phase 1 trial for CRB-601, a monoclonal antibody targeting advanced solid tumors.Quiver AI SummaryCorbus Pharmaceuticals Holdings, Inc. recently announced the dosing of the...

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

CRBP : 13.00 (-2.48%)
2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

VKTX : 42.25 (+1.83%)
CRBP : 13.00 (-2.48%)
NVO : 85.00 (-17.83%)
$SPX : 5,930.85 (+1.09%)
LLY : 767.76 (+1.35%)
Corbus Pharmaceuticals Receives FDA Fast Track Designation for CRB-701 in Treating Metastatic Cervical Cancer

Corbus Pharmaceuticals announced FDA Fast Track designation for CRB-701, targeting metastatic cervical cancer with a Phase 1 trial ongoing.Quiver AI SummaryCorbus Pharmaceuticals Holdings, Inc. announced...

CRBP : 13.00 (-2.48%)
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals: Q3 Earnings Snapshot

Corbus Pharmaceuticals: Q3 Earnings Snapshot

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

CRBP : 13.00 (-2.48%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar